[A18-61] Encorafenib (melanoma) - Benefit assessment according to §35a Social Code Book V
|Commission:||Commission awarded on 2018-09-27 by the Federal Joint Committee (G-BA)|
|Current document:||Executive summary of dossier assessment (German version) Further documents|
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
|Contact address:||to the contact form|
Encorafenib (melanoma) - Addendum to Commission A18-61
Status: Commission completed
|2019-01-02||Executive summary of dossier assessment (German version)||92 kB|
|2019-01-02||Dossier assessment (German version)||814 kB|
Federal Joint Committee (G-BA)
2019-03-22 A G-BA decision was published.